teenscreen-not-lab-rat.jpg

   The following announcement was posted on TeenScreen’s website (November 15, 2012):  "Important Announcement for Schools & Communities:  We are sorry to inform you that the TeenScreen National Center will be winding down its program at the end of this year. Accordingly, we will no longer train or register new programs."   http://www.teenscreen.org/ No explanation was…

Read More

FDA’s preeminent authority to determine whether a drug or device is approved is its assumed scientific expertise and honest, independent review of safety and performance data from scientifically valid, controlled clinical trials.  However, surveys of FDA scientists and numerous independent investigations by highly credible entities have all confirmed serious deficiencies in FDA’s scientific base and…

Read More

The latest area of controversy focuses on the proposed revision of the definition "behavioral addiction disorder" extending the addiction diagnosis to include drug, alcohol and gambling.  It is estimated that the change would expand the number of people labeled as "addicts" by 20 to 30 million who would be entitled to treatment and disability payments costing taxpayers many hundreds of millions of dollars.

Read More
jos._biederman.jpg

The primary promoters–inventors, one might say– of diagnosing children with "bipolar" disorder, who for over a decade, aggressively promoted the biopolar diagnosis and use of antipsychotics in children, were disciplined by Harvard University and its affiliated Massachusetts General Hospital.

Read More

Public Citzen petitioned  FDA Commissioner to immediately removal from market Pfizer’s Alzheimer’s drug, Aricept  23 mg dose, because of serious safety hazards and failure to demonstrate efficacy. The petition also urges FDA to add a label warning on Aricept and generic donepezil (5 mg and 10 mg) stating: "Use of 20 mg per day is counter indicated."

Read More

*More antipsychotic treatment was associated with smaller gray matter volumes. Progressive decrement in white matter volume was most evident among  patients who received more antipsychotic treatment.

Read More

New FDA antipsychotic Warnings:  "The symptoms of EPS and withdrawal in newborns may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding."

Read More

According to a report by the Associated Press, the FDA has approved expanded use of Merck’s toxic antipsychotic drug, Saphris, for treating acute manic-depressive behavior in adults. Antipsychotics (neuroleptics) are a controversial class of drugs: Risperdal (approved in 1993), Zyprexa (1994), Seroquel (1997), Abilify (2002), and Saphris (2009). These drugs’ safety hazzards were documented over…

Read More